Jounce Therapeutics, Inc. (NASDAQ:JNCE) enjoyed a 3.62% run-up in share price since hitting record low of $11.05. The stock managed -35.2% fall and now stands at $11.45 as of 05/17/2018. At recent session, the prices were hovering between $11.38 and $13. This company shares are 205.68% off its target price of $35 and the current market capitalization stands at $367.77M. The recent change has given its price a -46.66% deficit over SMA 50 and -60.85% deficit over its 52-week high. The stock witnessed -41.1% declines, -52.74% declines and -18.97% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JNCE’s volatility during a week at 11.18% and during a month it has been found around 8.26%.Jounce Therapeutics, Inc. (JNCE) Top Holders
Institutional investors currently hold around $526 million or 87.4% in JNCE stock. Look at its top three institutional owners. Trv Gp Ii, Llc owns $180.77 million in Jounce Therapeutics, Inc., which represents roughly 49.15% of the company’s market cap and approximately 34.37% of the institutional ownership. Similar statistics are true for the second largest owner, Trv Gp Iii, Llc, which owns 3,048,780 shares of the stock are valued at $53.87 million. The third largest holder is Fmr Llc, which currently holds $52.52 million worth of this stock and that ownership represents nearly 14.28% of its market capitalization.
At the end of 03/31/2018 reporting period, 54 institutional holders increased their position in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by some 2,791,535 shares, 43 decreased positions by 2,266,398 and 13 held positions by 24,706,144. That puts total institutional holdings at 29,764,077 shares, according to SEC filings. The stock grabbed 27 new institutional investments totaling 1,510,954 shares while 15 institutional investors sold out their entire positions totaling 979,654 shares.Jounce Therapeutics, Inc. (NASDAQ:JNCE) Insider Trades
Multiple company employees have indulged in significant insider trading. Jounce Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Duncan Barbara Gayle has sold 2,000 shares of Jounce Therapeutics, Inc. (JNCE) in trading session dated Mar. 15, 2018. These shares are worth $56,220 and were traded at $28.11 each. The SEC filing shows that Drapkin Kimberlee C performed a sale of 5,267 shares. The CFO and Treasurer disposed these shares by way of transaction on Mar. 08, 2018. The company’s shares were given away at $25.01 per share worth to an income of some $131,728 on account of Drapkin Kimberlee C.
CEO and President, Murray Richard /Ca/, sold 16,334 common shares of Jounce Therapeutics, Inc. (JNCE) in the open market. In a transaction dated Mar. 08, 2018, the shares were put up for sale at an average price of $25.1, raking in a sum of $409,983. After this sale, common shares of JNCE are directly owned by the insider, with total stake valued at $.
In the transaction dated Mar. 08, 2018, the great number of shares disposed came courtesy the Chief Medical Officer; Trehu Elizabeth disposed a total of 4,545 shares at an average price of $25.06, amounting to approximately $113,898. The insider now directly owns shares worth $.Jounce Therapeutics, Inc. (JNCE) Analyst Guide
Several analysts have released their opinion on Jounce Therapeutics, Inc. (NASDAQ:JNCE), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.